BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36406830)

  • 1. Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis.
    Roeser A; Jouenne F; Vercellino L; Calvani J; Goldwirt L; Lorillon G; Tazi A
    J Hematol; 2022 Oct; 11(5):185-189. PubMed ID: 36406830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans Cell Histiocytosis).
    Pegoraro F; Papo M; Cohen-Aubart F; Peyronel F; Lugli G; Trambusti I; Baulier G; de Menthon M; Le Scornet T; Oziol E; Ferreira-Maldent N; Hermine O; Faucher B; Koschel D; Straetmans N; Abisror N; Terrier B; Lifermann F; Razanamahery J; Allenbach Y; Keraen J; Bulifon S; Hervier B; Buccoliero A; Charlotte F; Monzani Q; Boussouar S; Shor N; Tondo A; Barete S; Idbaih A; Tazi A; Sieni E; Amoura Z; Emile JF; Vaglio A; Haroche J
    EClinicalMedicine; 2024 Jul; 73():102658. PubMed ID: 38841707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis.
    Aaroe A; Kurzrock R; Goyal G; Goodman AM; Patel H; Ruan G; Ulaner G; Young J; Li Z; Dustin D; Go RS; Diamond EL; Janku F
    Blood Adv; 2023 Aug; 7(15):3984-3992. PubMed ID: 36857436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
    Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Erdheim-Chester disease: a rare histiocytosis with outstanding response to cobimetinib.].
    Sosa GA; Dogliani P; Guidi AE; Marangoni MA; Lavarda M; Fainstein-Day P
    Rev Fac Cien Med Univ Nac Cordoba; 2021 Dec; 78(4):398-401. PubMed ID: 34962740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report.
    Kim S; Lee M; Shin HJ; Lee J; Suh YL
    Childs Nerv Syst; 2016 May; 32(5):893-6. PubMed ID: 26466952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rare case of Erdheim-chester disease reported from Nepal.
    Chhetri S; Manandhar S; Neupane D; Subedi SS; Chhetri S; Acharya A; Chaudhary S; Khatiwada P; Shrestha S
    Ann Med Surg (Lond); 2022 Aug; 80():104232. PubMed ID: 36045778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of class 3
    Wang C; Sandhu J; Fakih M
    J Gastrointest Oncol; 2019 Dec; 10(6):1140-1143. PubMed ID: 31949931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
    Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CNS Erdheim-Chester Disease: A Challenge to Diagnose.
    Pan Z; Kleinschmidt-DeMasters BK
    J Neuropathol Exp Neurol; 2017 Dec; 76(12):986-996. PubMed ID: 29096034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
    Abla O; Weitzman S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia.
    Bonometti A; Ferrario G; Parafioriti A; Giardino D; Simonetti F; Ginori A; Passoni E; Berti E;
    J Cutan Pathol; 2021 May; 48(5):637-643. PubMed ID: 33188581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
    Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
    Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
    Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
    Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Patient with Erdheim-Chester Disease Limited to Central Nervous System.
    Gupta RK; Haque A; Reddy TA; Pérez CA
    Neurol Int; 2022 Aug; 14(3):678-682. PubMed ID: 36135991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case of Erdheim-Chester presenting with xanthelasma-like eruption and osteolytic bone lesions: A case report.
    Chinchilla EA; Gourde MP; Turcotte K; Mathieu S; Amin-Hashem M
    SAGE Open Med Case Rep; 2019; 7():2050313X19845217. PubMed ID: 31105942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K
    Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary manifestations of Erdheim-Chester disease: clinical characteristics, outcomes and comparison with Langerhans cell histiocytosis.
    Wang JN; Wang FD; Sun J; Liang ZY; Li J; Zhou DB; Tian X; Cao XX
    Br J Haematol; 2021 Sep; 194(6):1024-1033. PubMed ID: 34423426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
    Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.